This compound is a key chiral intermediate in the synthesis of Amprenavir, a protease inhibitor used for HIV-1 infection treatment. As a critical building block, it constructs the core structure of Amprenavir by providing the (1S,2R)-hydroxyamine moiety and (3S)-tetrahydrofuranyl carbamate group, essential for binding to HIV protease. Its high enantiomeric purity ensures the correct stereochemistry of the final drug, directly impacting efficacy and safety. Beyond pharmaceutical synthesis, it serves as a reference standard in chiral HPLC analysis for quality control of Amprenavir and related antiretrovirals. In organic chemistry, it is used to study stereoselective synthesis of complex molecules with multiple chiral centers. Due to its stable crystalline form and well-defined reactivity, it is widely adopted in GMP-compliant pharmaceutical manufacturing and academic research for developing novel protease inhibitors.
This substance is classified as GHS07 (Warning) with mild to moderate hazards. H315: Causes skin irritation; H319: Causes serious eye irritation; H335: May cause respiratory irritation. No acute oral toxicity data (LD?? >2000 mg/kg, rat), indicating low acute toxicity. Inhalation of dust may irritate the respiratory tract, causing cough or throat discomfort. Skin contact may lead to redness, itching, or mild dermatitis, especially with prolonged exposure. Eye contact can cause stinging, tearing, and conjunctival inflammation. It is combustible but not highly flammable; avoid strong oxidants, which may trigger reactions. Handle in well-ventilated fume hoods, wearing nitrile gloves, safety goggles, and dust masks. In case of skin contact, rinse with plenty of water for 15 minutes; for eye contact, flush with water and seek medical help. Store in cool, dry, dark areas away from heat and incompatible substances. Dispose as hazardous waste per local regulations.
